News

 

Contact Media Relations

Office telephone: +39 0331 581380
mediarelations@nmsgroup.it

Serena Alvino Appointed as Chief Legal, Biotech & Transaction NMS Srl, Bringing Extensive Global Biopharmaceutical Experience

Serena Alvino Appointed as Chief Legal, Biotech & Transaction NMS Srl, Bringing Extensive Global Biopharmaceutical Experience

NERVIANO, IT and BOSTON, Mass, December 1, 2023 – Nerviano Medical Sciences S.r.l. (NMS), a part of NMS Group S.p.A. (NMS Group) and Nerviano Medical Sciences, Inc., a wholly owned subsidiary of NMS Group, focused on the discovery and development of oncology drugs and the largest oncological R&D company in Italy, announced today the appointment of Serena Alvino as its Chief Legal, Biotech & Transaction, effective immediately.

(Click the title for the complete article)

NerPharMa Appoints Claudio Salvagnini as Deputy CEO

NerPharMa Appoints Claudio Salvagnini as Deputy CEO

Nerpharma is pleased to announce the appointment of Claudio Salvagnini as the Deputy CEO, effective immediately.

Since Claudio joined the leadership team earlier this year, he has been a driving force in the recent turning around NerPharMa. As the Deputy CEO, he will play a critical role in shaping the company’s strategic direction and ensuring operational efficiency.

(Click the title for the complete article)

NMS Srl proudly takes part of the Mentoring Program 2024 organized by the Italian Chemical Society

NMS Srl proudly takes part of the Mentoring Program 2024 organized by the Italian Chemical Society

We are pleased to announce that Dr. Gianluca Papeo and Dr. Maurizio Pulici from NMS Srl are invited to be part of the permanent round table of the Pharmaceutical Division of the Italian Chemical Society (SCI) which gathers representative of the Italian Pharmaceutical industry and the Academic world to liaise their relationships under the patronage of the SCI.

(Click the title for the complete article)

Tiziano Lazzaretti Appointed as CFO to Drive Financial Strategy at NMS Srl

Tiziano Lazzaretti Appointed as CFO to Drive Financial Strategy at NMS Srl

Nerviano Medical Sciences S.r.l., a part of NMS Group S.p.A. (NMS Group) and Nerviano Medical Sciences, Inc., a wholly owned subsidiary of NMS Group, focused on the discovery and early development of oncology drugs and the largest oncological R&D company in Italy, announced today the appointment of Tiziano Lazzaretti as its new Chief Financial Officer (CFO). Tiziano brings a wealth of leadership experience in corporate strategies, finance, and governance, acquired across diverse industries, including chemicals, pharmaceuticals and biotechnology sectors.

(Click the title for the complete article)

Nerviano Medical Sciences S.r.l. to Present Preliminary Phase 1 PARP1 selective inhibitor data at the 35th AACR-NCI-EORTC 2023: Poster

Nerviano Medical Sciences S.r.l. to Present Preliminary Phase 1 PARP1 selective inhibitor data at the 35th AACR-NCI-EORTC 2023: Poster

NERVIANO, IT and BOSTON, Mass, October 12, 2023 – Nerviano Medical Sciences S.r.l., a part of NMS Group S.p.A. (NMS Group) and Nerviano Medical Sciences, Inc., a wholly owned subsidiary of NMS Group, focused on the discovery and early development of oncology drugs and the largest oncological R&D company in Italy, reported today, initial results from the dose escalation parts of two Phase I-I/II studies for NMS-03305293 (NMS-293). As an oral, brain penetrant PARP-1 selective inhibitor, NMS-293 has shown strong antitumor activity and complete tumor regression in BRCA mutated preclinical models as a single agent. NMS-293 shows remarkable selectivity towards PARP-1 and efficiently inhibits cellular PARP activity resulting in selective antiproliferative responses on BRCA mutated cell lines. Furthermore, NMS-293 is synergistic and well tolerated in combination with temozolomide (TMZ) in both MGMT methylated and MGMT unmethylated glioblastoma mouse models. For the first time, clinical data is being presented during the poster session (Abstract 37568) at the AACR-NCI-EORCT 2023 Annual Meeting in Boston, Massachusetts. The poster will be available today on the NMS websites.

(Click the title for the complete article)

Nerviano Medical Sciences to Present Preliminary Phase 1 PARP1 selective inhibitor data at the 35th AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics

Nerviano Medical Sciences to Present Preliminary Phase 1 PARP1 selective inhibitor data at the 35th AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics

NERVIANO, IT and BOSTON, Mass, October 2, 2023 – Nerviano Medical Sciences S.r.l., a part of NMS Group S.p.A. (NMS Group) and Nerviano Medical Sciences, Inc., a wholly owned subsidiary of NMS Group, focused on the discovery and early development of oncology drugs and the largest oncological R&D company in Italy, announced today it will present initial data from the PARP1 inhibitor Phase 1 studies at the upcoming AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics, being held October 11-15 in Boston, MA.

(Click the title for the complete article)

Alternative Method developed by Accelera – Metodo alternativo sviluppato da Accelera

Alternative Method developed by Accelera – Metodo alternativo sviluppato da Accelera

On September 21st were presented at the EU Commission Joint Research Center in Ispra the results of the method “Inhibition of thyroid hormones glucuronidation using liquid chromatography/mass spectrometry” developed by Accelera within the frame of the EU-NETVAL project, aimed at implementing new alternative (non-animal) methods to assess the potential disrupting effect of chemicals on the thyroid.

(Click the title for the complete article)

Nerviano Medical Sciences S.r.l. to present data on its ADC platform at the World ADC Summit  2023 in San Diego CA (Oct 16th-Oct 19th, 2023)

Nerviano Medical Sciences S.r.l. to present data on its ADC platform at the World ADC Summit 2023 in San Diego CA (Oct 16th-Oct 19th, 2023)

Nerviano Medical Sciences S.r.l., a member of NMS Group S.p.A and a clinical stage biotech discovering and developing innovative therapies for the treatment of cancer, is proud to announce its participation to the World ADC 2023 summit that will be held in San Diego (CA) from October 16th to October 19th, 2023, with two poster presentations

(Click the title for the complete article)

 Our Archive

MEDIA RELEASES & NEWS 2020
MEDIA RELEASES & NEWS 2019
MEDIA RELEASES & NEWS 2018
MEDIA RELEASES & NEWS 2020
MEDIA RELEASES & NEWS 2019
MEDIA RELEASES & NEWS 2018

 

Welcome and Check out our new motion picture!

WATCH OUR VIDEO